Other Content - BioPharm International

ADVERTISEMENT

Other Content

Johnson & Johnson's Pharma Sector Poised for Growth, 10 New Product Filings Expected by 2017

May 28, 2013

Johnson & Johnson anticipates submitting more than 10 new product filings and more than 25 significant brand line extensions by 2017; the announcement was made at a recent meeting with industry analysts. Upcoming new products include simeprevir for hepatitis C (already filed in Japan, Europe and the US); ibrutinib and daratumumab for haematologic malignancies; sirukumab and guselkumab for diseases of the immune system such as rheumatoid arthritis and psoriasis; and vaccines for influenza, rabies and polio.

ADVERTISEMENT

ADVERTISEMENT

Click here